rolipram has been researched along with Chronic Disease in 4 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effect of rolipram, a selective PDE4 inhibitor, with steroids on the clinical course of experimental colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS)." | 3.73 | Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. ( Guarner, F; Malagelada, JR; Medina, C; Mourelle, M; Salas, A; Videla, S; Vilaseca, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Titus, DJ | 1 |
| Sakurai, A | 1 |
| Kang, Y | 1 |
| Furones, C | 1 |
| Jergova, S | 1 |
| Santos, R | 1 |
| Sick, TJ | 1 |
| Atkins, CM | 1 |
| Kumar, N | 1 |
| Goldminz, AM | 1 |
| Kim, N | 1 |
| Gottlieb, AB | 1 |
| Videla, S | 1 |
| Vilaseca, J | 1 |
| Medina, C | 1 |
| Mourelle, M | 1 |
| Guarner, F | 1 |
| Salas, A | 1 |
| Malagelada, JR | 1 |
| Folcik, VA | 1 |
| Smith, T | 1 |
| O'Bryant, S | 1 |
| Kawczak, JA | 1 |
| Zhu, B | 1 |
| Sakurai, H | 1 |
| Kajiwara, A | 1 |
| Staddon, JM | 1 |
| Glabinski, A | 1 |
| Chernosky, AL | 1 |
| Tani, M | 1 |
| Johnson, JM | 1 |
| Tuohy, VK | 1 |
| Rubin, LL | 1 |
| Ransohoff, RM | 1 |
1 review available for rolipram and Chronic Disease
| Article | Year |
|---|---|
Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Topics: Autoimmune Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2013 |
3 other studies available for rolipram and Chronic Disease
| Article | Year |
|---|---|
Phosphodiesterase inhibition rescues chronic cognitive deficits induced by traumatic brain injury.
Topics: Animals; Brain Injuries; Chronic Disease; Cognition Disorders; Conditioning, Psychological; Cyclic A | 2013 |
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Chronic Disease; Colitis; Colon; Cyclic Nucleotide Pho | 2006 |
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Animals; Blood-Brain Barrier; Brain Edema; Centr | 1999 |